Clinical trial · Observational

Exploring the Possibility to Use Glycosyltransferase as a Prognosis Marker of Neuroblastoma

NCT01638572CI-TRIAL-00007382completedClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

Well-regulated glycosylation is essential for the normal development of the nervous system. Altered expression of glycosyltransferases with resulting dysregulated glycosylation of neuroblastic cells might lead to the development of NB. The β1,4-N-acetylgalactosaminyltransferase III (B4GALNT3) exhibits GalNAc transferase activity to form the GalNAcβ1,4GlcNAc (LacdiNAc or LDN) structure. The Drosophila B4GALNTA, homolog of human B4GALNT3, has been suggested to regulate the neuronal development. By immunohistochemical studies, we demonstrated that the expression of B4GALNT3 correlated well with histological grade of differentiation in NB tumor samples. Since well differentiated tumors usually carry a better prognosis, we thus speculate that expression of B4GALNT3 in tumor tissues can a favorable prognostic factor of NB. To explore the role of B4GALNT3 in the prognosis of NB, we propose the following project with two specific aims: Aim Ⅰ: Establishing the significance of B4GALNT3 in the prognosis of NB: We plan to collect 90 NB tumor samples, and evaluate the RNA and protein expression levels by Q-PCR, Western blot, and immunohistochemistry in the tumor samples. The results will be compared with the other clinicopathological and biological factors of NB. Also the expression levels of B4GALNT3 in tumor tissues will be correlated to the patients' outcome to clarify whether B4GALNT3 could be a prognosis marker of NB. Aim II: Clarifying the effects of B4GALNT3 on NB cell behavior in vitro and in vivo. For further strengthening the prognostic role of B4GALNT3 in NB, NB cell phenotype and behavior changes after overexpression or knock-down of B4GALNT3 are evaluated by in vitro assays as well as by a nude mice xenograft model. In summary, if our project can establish the role of B4GALNT3 expression in NB, we may further subclassify the NB patients, and give the NB patients more appropriate therapies to improve patients' outcome. Furthermore, B4GALNT3 could potentially serves as a therapeutic target in the future.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Neuroblastoma	Neuroblastoma	ONTOLOGY_EXACT	0.90

Interventions

Interventions (0)

Data not yet available

No intervention recorded.

Design

Arms and outcomes

Arms (1)

label
neuroblastoma patients

Primary outcomes (0)

[]

Eligibility

Eligibility (as posted)

Sex: All
Maximum age: 18 Years

Show eligibility criteria text

Inclusion Criteria:

* Neuroblastoma patients with complete follow-up and sufficient samples for study

Exclusion Criteria:

* Neuroblastoma patients without complete follow-up or sufficient samples for study

References

Publications (0)

Data not yet available

No reference posted for this study.

Registry

Dates and enrollment

Start: Jan 1, 2010
Primary completion: Dec 1, 2011
Completion: Dec 1, 2011
First posted: Jul 11, 2012
Last update posted: Jul 11, 2012
Enrollment: 90 (actual)
Lead sponsor: National Taiwan University Hospital OTHER
Keywords: Neuroblastoma, B4GALNT3, Prognosis

Data updated 22 days agoSource updated Jul 11, 2012source: clinicaltrials

Locations

Locations by country (1)

Country	Sites	Recruiting
Taiwan	1	0

Trial listing is informational. Eligibility is decided by the study team; contact information is on ClinicalTrials.gov.